Catalyst Crew Technologies Corp. (OTC: CCTC) announced today that it has assigned three Venezuelan patents to its wholly-owned subsidiary, Inversiones Long 33, C.A., as part of a broader strategy to consolidate intellectual property and support international growth. The patents, previously held by CEO Dr. Kevin Rodan Levy, cover proprietary technologies known as CardioAI, PulmoAI, and NeuroAI, which are designed to enhance data-driven healthcare analytics, predictive modeling, and clinical decision-support applications.
The Company believes that placing these assets directly under its operating subsidiary will improve strategic flexibility, facilitate regulatory compliance, and create opportunities for partnerships and licensing deals in Latin America and beyond. “Aligning our intellectual property within our operating structure is an important step as we continue building our platform,” said Dr. Levy. “Establishing a clear foundation around our core technologies allows us to move forward with development, partnerships, and, where appropriate, broader intellectual property protection strategies across additional markets.”
Catalyst Crew Technologies is a digital health and AI company focused on emerging markets, with an initial emphasis on Latin America. Its platform includes telehealth infrastructure, remote patient monitoring, and advanced healthcare analytics aimed at improving access, efficiency, and care coordination. The assigned patents are central to these offerings, and the Company intends to pursue expanded IP protection in other jurisdictions to support long-term platform development and potential international deployment.
This assignment follows the Company’s strategic transition into AI-enabled healthcare and its efforts to build an integrated technology platform through development, partnerships, and targeted acquisitions. While still a development-stage enterprise without revenues from its new direction, Catalyst Crew Technologies is positioning itself to address growing demand for modernized healthcare delivery systems in emerging markets.
For more information, visit https://catalystcrewai.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
